The ADJUVANT trial compared gefitinib (oral for two years) with cisplatin plus vinorelbine (four cycles) in stage II–IIIA NSCLC patients with common EGFR mutations (exon 19 deletion or exon 21 L858R mutation) after complete resection [41]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.